Enantiomeric antidepressant drugs should be considered on individual merit

Human Psychopharmacology

Volumn 16, Issue SUPPL. 2, 2001, Pages

  Baumann, Pierre ^a   Eap, Chin B ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Antidepressant; Citalopram; Depression; Enantiomer; Escitalopram; Stereochemistry

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ARTICLE; CHIRALITY; CONTROLLED STUDY; DEPRESSION; DRUG INTERACTION; DRUG METABOLISM; DRUG MONITORING; DRUG RECEPTOR BINDING; ENANTIOMER; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RACEMIC MIXTURE; RISK BENEFIT ANALYSIS; STEREOCHEMISTRY;

EID: 0035673997     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.336     Document Type: Article

References (35)

1. Intellectual property and chirality of drugs
2. Stereo-selective disposition of mianserin is related to debrisoquine hydroxylation polymorphism
3. 2-selective adrenoceptor antagonist org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission
4. Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients
5. Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: Interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics
6. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquin
7. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report
8. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers
9. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5 phenotyped patients
10. The stereo-selective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
11. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population
12. Fluoxetine
13. Trimipramine: Pharmacological reevaluation and comparison with clozapine
14. Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioural screen for antidepressant activity
15. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
16. A comparison of the physicochemical and biological properties of mirtazapine and mianserin
17. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers
18. Paroxetine increases serum trimipramine concentration: A report of two cases
19. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
20. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients
21. Venlafaxine oxidation in vitro is catalysed by CYP2D6
22. Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: Are they responsible for the antidepressant effect?
23. The potential therapeutic role of the enantiomers and metabolites of mianserin
24. Citalopram: A comprehensive review
25. Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine
26. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes
27. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver
28. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males
29. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
30. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans
31. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
32. Clinical pharmacokinetics of mirtazapine
33. Chiral switches
34. Pharmacokinetic consequences of a citalopram treatment discontinuation
35. 3 receptors